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A poorly defined transforming event(s) affects the pluripoten- 
tiai bone marrow (BM) stem cell in myelodysplastic syndromes 
(MDS), conferring a growth advantage upon it which leads 
eventually to monoclonal hematopoiesis. The progeny of this 
transformed ancestor undergo recognizable albeit dysplastic 
maturation. We propose that this picture is further complicated 
by a variety of cytokines, tumor necrosis factor alpha (TNF-a), 
transforming growth factor beta (TGF-/3) and interleukin 1 p (IL- 
1/3) which exert a dual effect on the diseased cells. The imma­
ture CD34+ cells are stimulated to proliferate, while their later 
differentiated daughters are induced to undergo apoptosis 
accounting for the clinical syndrome of pancytopenia despite 
hypercellular BMs. Studies directed at measuring the rates of 
proliferation and apoptosis as well as the levels of TNF-a, TGF-
0 and 1L-1/3 confirm this hypothesis and are presented in 
greater detail. A novel approach towards MDS therapy emerges 
as a result of this paradigm shift based upon the premise that 
anti-cytokine therapy would prevent excessive intramedullary 
apoptosis and result in improved cytopenias as well as cause 
a slowing down of the diseased precursor cell proliferation 
resulting in resumption of poiycional hematopoiesis. Because 
a number of cytokines function through common lipid second 
messengers, interruption of this pathway should theoretically 
cause disruption in the signalling of a cascade of cytokines. 
Keywords: myelodysplastic syndromes (MDS); tumor necrosis fac­
tor alpha (TNF-a); transforming growth factor beta (TGF-j3); interleu­
kin 1/3 (IL-1/3); apoptosis
Introduction
The myelodysplastic syndromes (MDS) are indolent clonal dis­
orders which predominate in the elderly and which clearly 
involve a diseased pluripotential hematopoietic stem cell 
since monoclonality of at least the non-lymphoid cells is the 
rule,1-5 The clinical presentation poses an apparent paradox in 
that the majority of patients have variable cytopenias despite 
hypercellular marrows. Approximately 30% patients evolve 
into acute leukemia which is commonly of the myeloid var­
iety, although lymphoid transformation has also been clearly, 
albeit rarely, demonstrated in these patients.6"10 Abnormalities 
of chromosomes 5 and 7 are rather common followed by 
those affecting chromosomes 8, 20 and 17.11~14 The only 
treatment option for the majority of MDS patients continues 
to be supportive care since various therapeutic approaches 
ranging from the use of vitamins and growth factors to inten­
sive chemotherapy have failed to benefit a substantial number 
of patients.15' 17 Given this depressing clinical scenario, efforts 
have been focused at understanding the biology of MDS better
with the hope of developing objective and rational treatment 
approaches assigned to reverse the lesion(s). Our own studies 
combined with those of others over the last 10 years have 
allowed us to develop a new model for the pathogenesis of 
MDS which we believe constitutes a paradigm shift in these 
disorders. The purpose of this article is to summarize these 
studies and present the new paradigm.
MDS is a stem cell disease
Highly sophisticated biochemical and molecular studies have 
repeatedly demonstrated that the bone marrow in MDS pati­
ents is monoclonal.18“23 This monoclonality should not be 
confused with the monoclonality of malignancy. For example, 
de novo standard risk primary acute myeloid leukemia (AML) 
is a monoclonal disease, but here the clonality refers to only 
the leukemic cells or blasts, while the residual hematopoietic 
cells are usually not clonal.24 In MDS on the other hand, the 
BM consists of cells belonging to erythroid, myeloid and 
megakaryocytic lineages (as well as probably the B 
lymphocytes) at all stages of differentiation (albeit dysplastic) 
but all of which are the descendants of one single diseased 
parent $tem cell. In other words, the transforming event in the 
stem cell conferred upon it a growth advantage so that the 
entire 'feeder' compartment of pluripotential cells was over­
whelmed by the progeny of the transformed cell (see Figure 1). 
In this sense, MDS is closer to the chronic phase of chronic 
myeloid leukemia (CML) where the (normally) differentiated
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Figure 1 Killman's model of normal hematopoiesis has been util­
ized to describe the paradigm shift in myelodysplastic syndromes. 
Note that the 'initial event(s)' in MDS affects a stem cell in the 'feeder' 
compartment while commonly encountered cytogenetic abnormali­
ties affecting chromosome 5, 7, 8 etc are later evolutionary events.
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erythroid, myeloid and megakaryocytic cells are all marked 
by the pathognomonic Philadelphia (Ph') chromosome.25 In 
CM L, the initial 'event' appears to be the Ph' translocation 
since the BM resumes a polyclonal nature upon disappear­
ance of this cytogenetic abnormality in response to interferon 
therapy.25 In MDS on the other hand, cytogenetic abnormali­
ties such as those affecting chromosomes 5 or 7 appear to be 
epiphenomena or secondary events since they often involve 
a proportion of cells in a marrow which is otherwise mono­
clonal.11'26 In MDS therefore, the first consequence of the 
transforming event is monoclonality and cytogenetic abnor­
malities represent disease evolution while in CML, the Ph' 
translocation may be the 'transforming event' since there is 
no evidence of monoclonal hematopoiesis upon eradication 
o f the Ph' chromosome. The model of normal hematopoiesis 
proposed by Killman27 is particularly relevant in this setting 
(Figure 1).
Nature of the transforming event is obscure and ambiguous 
in MDS
MDS patients to another, if not varying amongst individuals. 
Whatever the initial event is in MDS, its consequences are 
very well appreciated. The affected cell develops a growth 
advantage over its neighbors eventually leading to mono­
clonal hematopoiesis. Once the entire BM is descending from 
a single parent cell, the likelihood of additional mutations 
accumulating in one of its daughters is very great. Further, 
the evolved and additionally mutated cell will have a greater 
chance of survival and future proliferation in a monoclonal 
setting as compared to a polyclonal one because all the sur­
rounding sister cells share in the same initial event' and thus 
are not very different from it The expansion (and perhaps 
further mutations) of one such clone is probably responsible 
for the eventual evolution to acute leukemia, The key conse­
quence of the stem cell defect in MDS then is monoclonality 
which predisposes these patients to frank malignancy. In fact, 
the definition of pre-leukemia should perhaps be rendered 
more objective by restricting the term to individuals in whom 
monoclonality (in the absence of a substantial number of 
blasts) can be documented.
Since there are certain cytogenetic abnormalities which occur 
in MDS with a regular frequency, it is not unreasonable to 
look for genic abnormalities associated with the most com­
monly involved areas of the affected chromosomes. In MDS, 
the interstitial deletion involving 5q31J with its associated 
loss of the IRF-1 gene is one such abnormality.20 The 5q31.1 
deletion is present in 30% MDS patients and 50% AML pati­
ents who developed leukemia secondary to a preceding mye­
lodysplasia.20 Located at this site is the transcription 
enhancer/tumor suppressor IRF-1 gene29 which can also be 
functionally inactive due to accelerated 'exon skipping' 
despite the presence of a normal gene.30 It is also possible 
that exaggerated exon skipping in the allele containing the 
normal IRF-1 superimposed upon the deleted IRF-1 allele 
accounts for the evolution of MDS to AML. Conversely, over­
expression of IRF-2 can suppress the effects of IRF-1.31 The 
problem with implicating the IRF-1 in the 'transforming event' 
is that this deletion was detected in only 20-80% of the hema­
topoietic cells in MDS patients correlating with the percentage 
of blasts27 rather than the 100% of the cells expected on the 
basis of the monoclonal nature of the disease. In other words, 
a genetic abnormality which only affects a proportion of the 
M D S cells instead of all the monoclonal cells by definition 
cannot be a candidate for the transforming event.
Inappropriate expression of another gene, the esotropic 
virus integration site 1 gene (Evi-1) associated with retrovirally 
induced myeloid leukemias in mice32 has also been associ­
ated with AML and MDS in humans.33 Aberrant expression of 
Evi-1 conferred a non-responsiveness in murine BM progeni­
tor cells to the effects of erythropoietin, an observation parti­
cularly relevant to MDS since the erythroid cells appear to be 
universally most diseased in these disorders. Because abnor­
malities of Evi-1 are not found in all MDS patients, once again 
it is difficult to consider this gene as being somehow involved 
in the initial 'transforming event'. Other molecular lesions 
which have been described include mutations of rasy34 fms,35 
p53;ift as well as deregulation of other as yet unidentified 
tumor suppressor genes.37
In summary therefore, MDS are clearly stem cell disorders 
although the nature of the initial event is unknown. Given that 
these complex syndromes are highly heterogeneous in their 
clinical presentations, it is likely that the initial event(s) will 
parallel this heterogeneity being different from one group of
What causes the clinical syndrome of MDS?
The apparent paradox of variable cytopenias in the presence 
of generally cellular marrows in these patients could be 
accounted for by increased proliferation of hematopoietic 
cells being cancelled by an equally increased rate of intrame- 
dullary apoptosis. Thus, despite frantic activity in the marrow 
compartment, the peripheral blood would remain devoid of 
functional hematopoietic cells. In fact, our own studies 
directed at measuring the in vivo rates of proliferation and 
programmed cell death have demonstrated the above hypoth­
esis to be quite true. By infusing MDS patients with thymidine 
analogues iodo- and/or bromodeoxyuridine (lUdR, BrdU) as 
previously described,™'39 we found that the total cell cycle 
time (Tc) in 120 MDS patients was a median of 35 h while 
the labeling index (LI) was 26.1%. Figure 2 shows a double­
labeled slide in an MDS patient where large numbers of cells 
can be seen synthesizing DNA. Thus, MDS are clearly actively 
proliferative disorders with no dearth of S-phase cells in their 
bone marrows. Unfortunately, the rapid proliferation Is coun­
tered by rapid and excessive cell death.
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Figure 2 Double labeling for the two thymidine analogues iodo- 
deoxyuridine (lUdR) (brown) and bromodeoxyuridine (BrdU) (blue) 
depicting the cells synthesizing DNA in the bone marrow biopsy of 
an MDS patient. Original magnification x400.
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Figure 3 In situ end labeling (ISEL) of fragmented DMA in MDS 
bone marrow biopsy showing high percentage of cells undergoing 
apoptosis. Original magnification x400.
Apoptosis in the BM biopsies of MDS patients was meas­
ured using the technique of in situ end labeling (ISEL) of frag­
mented DNA40-44 and found to be very high as compared to 
normal or AML marrows.43,44 Among 102 MDS patients stud­
ied by ISEL, approximately half showed 30-50% cells 
undergoing apoptosis in their biopsies. Figure 3 shows a typi­
cal MDS BM biopsy. Double-labeling for proliferation 
(lUdR/BrdU) and apoptosis (ISEL) simultaneously showed 
large numbers of S-phase cells to be apoptotic (Figure 4) rais­
ing the question of 'antonymous' death in MDS.45 Thus, while 
the BM in MDS patients is packed with proliferating cells, they 
are also in the process of concomitantly committing suicide. 
This may account for the paradox of pancytopenia despite 
hypercellularity of the marrow,
Could dual-acting cytokines be responsible for the 
excessive cell-birth and ceil-death in MDS bone marrows?
apoptosis in hematopoietic cells.46-48 it is conceivable that 
one or more of these cytokines are causing the stimulation of 
early CD34+ progenitor cells in the BM while inducing 
apoptosis in their maturing progeny. Indeed, we have demon­
strated higher than expected levels of all three cytokines in 
MDS patients.49 What is the source of these cytokines? Either 
they are being produced by the transformed cells themselves 
as a mode of autostimulation or they are being secreted by 
the 'normal' monocytes/macrophages in the body's attempt to 
contain the expanding monoclonal population of transformed 
cells. Whatever the source, their effect is detrimental at two 
levels since they end up stimulating the offending premature 
CD34* blasts while destroying the maturing CD34” cells.
A paradigm shift
Figure 5 presents the new paradigm, A poorly defined initial 
event(s) leads to unrestrained growth of the abnormal cell 
eventually overwhelming the entire BM as demonstrated by 
studies of 'monoclonality'. Presence of cytokines whose 
source also remains unexplained at the moment, confounds 
the picture further by stimulating the early precursors and 
destroying the later forms most likely accounting for the clini­
cal syndrome of pancytopenia and hypercellular bone mar­
rows, The commonly encountered cytogenetic abnormalities 
probably represent later evolutionary events since these are 
not usually present in every BM cell. When MDS patients 
evolve to AML, there are distinct additional events, ie loss of 
differentiation in the leukemic clone and therefore loss of 
apoptosis. Implicit in the above is of course the loss of cyto­
kine-induced effects and therefore an assumption of more 
autonomous growth by the leukemic clone. Treatment out­
come of such secondary AML patients is distinctly inferior to 
primary AML probably because the cell involved is decidedly 
more primitive in the former (belonging to the 'feeder' pool) 
as compared with the latter (belonging to the 'committed' 
myeloid progenitor).
A variety of cytokines such as tumor necrosis factor alpha 
(TNF-ct), transforming growth factor beta (TGF-j3) and interleu­
kin 1 beta (IL-1/3) along with IL-1/3 converting enzyme (ICE) 
can have dual effects of stimulating proliferation and inducing
Figure 4 Simultaneous presence of cell birth (brown) and cell 
death (blue) demonstrating the phenomena of antonymy in MDS bone 
marrow biopsy. Original magnification xlOOO.
Novel therapies resulting from the new paradigm
By the time MDS patients present to their physicians with the 
full-blown clinical syndrome, several additional abnormalities 
have probably already followed the initial transforming event. 
Attempts to reverse each of the genic events may be some
? IRF-1, EvM, 
ras, p53 etc
Cytokines
( ?TNFhjl, TGF-P, 
IL1P / ICE)
Apoptosis
Figure 5 The new paradigm for MDS.
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way in the future. The clinical symptoms however may be a 
result of the confounding actions of cytokines and therefore 
one could attempt to neutralize some of these effects with the 
expectation of clinical benefit. In the past, this approach of 
biotherapy in MDS has been restricted to the use of 'viability 
factors' such as interleukin-3 (IL-3), granulocyte colony-stimu- 
lating factor (G-CSF) or granulocyte-macrophage CSF (GM- 
CSF) and erythropoietin or their combinations. These trials 
have resulted in selective and variable benefits in a number 
of MDS patients.50“52 Unfortunately, the responses have been 
mostly transient and often the side-effects preclude prolonged 
trials.50 52 Chemotherapeutic trials have been equally toxic 
and unimpressive and could only be attempted in patients 
with excess blasts.15 Combinations of growth factors and 
chemotherapy have been tried with similar results.53 Obvi­
ously, these approaches may be refined further in the future 
when newer agents such as thrombopoietin and chemo­
therapies such as topotecan are introduced into clinical trials 
in MDS patients. W e  propose a novel approach to MDS ther­
apy based on the new paradigm. Why not try anti cytokine 
therapy which would neutralize the noxious cytokines thereby 
producing a dual effect of ameliorating cytopenias (by sup­
pressing apoptosis) and decrease the proliferation of the trans­
formed clone leading to resumption of polyclonality? What 
are the candidate agents in this area?
First, a cascade of cytokines including TNF-a, TGF-j3 and 
IL-1J3 act via the phosphatidic acid (PA) —► diacylglycerol 
(DAG) lipid signalling pathway.54-59 Interruption of this 
second messenger system by drugs such as pentoxifylline57 
and ciprofloxacin5“ or lisophylline™ could be tried, Second, 
specific inhibition of individual cytokines could be attempted 
by use of soluble TNF-a receptor or IL-1 /3 receptor antagonists 
given to patients in vivo. Finally, a combined "multi-modality' 
approach using viability factors and chemotherapy alternating 
with the anticytokine approach may be a far more valuable 
strategy than using any one of the above alone. The idea is 
that a whole new area of clinical trials has been opened up 
by the construction of this new paradigm. Further therapeutic 
advances will occur only if we do not throw the baby out with 
the bath water and make sure that parallel detailed biological 
studies are conducted with the trial of every new agent(s) in 
order to define the reasons for response and non-response.
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